Inflammatory bowel disease: clinical aspects and established and evolving therapies
DC Baumgart, WJ Sandborn - The Lancet, 2007 - thelancet.com
Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders. In
this paper we discuss the current diagnostic approach, their pathology, natural course, and …
this paper we discuss the current diagnostic approach, their pathology, natural course, and …
Treatment of inflammatory bowel disease (IBD)
AB Pithadia, S Jain - Pharmacological Reports, 2011 - Springer
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have …
tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have …
Clinical aspects and pathophysiology of inflammatory bowel disease
BA Hendrickson, R Gokhale… - Clinical microbiology …, 2002 - Am Soc Microbiol
The chronic inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are
recognized as important causes of gastrointestinal disease in children and adults. In this …
recognized as important causes of gastrointestinal disease in children and adults. In this …
AGA technical review on perianal Crohn's disease
WJ Sandborn, VW Fazio, BG Feagan, SB Hanauer - Gastroenterology, 2003 - Elsevier
AGA technical review on perianal Crohn’s disease - ScienceDirect Skip to main contentSkip to
article Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue …
article Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue …
Thalidomide
ME Franks, GR Macpherson, WD Figg - The Lancet, 2004 - thelancet.com
Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer
and inflammatory diseases. Although the evolution of its clinical application could not have …
and inflammatory diseases. Although the evolution of its clinical application could not have …
Optimizing anti-TNF treatment in inflammatory bowel disease
P Rutgeerts, G Van Assche, S Vermeire - Gastroenterology, 2004 - Elsevier
Infliximab, the chimeric monoclonal immunoglobulin (Ig) G1 antibody to tumor necrosis
factor (TNF) has changed our therapy of Crohn's disease. Infliximab is indicated in refractory …
factor (TNF) has changed our therapy of Crohn's disease. Infliximab is indicated in refractory …
Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics
F Shanahan - Gastroenterology, 2001 - Elsevier
Treatment options for inflammatory bowel disease (IBD) reflect a continuing shift from
empiricism to strategies based on improved understanding of the pathophysiology of …
empiricism to strategies based on improved understanding of the pathophysiology of …
Tumor necrosis factor: biology and therapeutic inhibitors
KA Papadakis, SR Targan - Gastroenterology, 2000 - Elsevier
Tumor necrosis factor (TNF) was originally described as a protein factor capable of killing
tumor cells in vitro and causing hemorrhagic necrosis of transplantable tumors in mice. 1, 2 …
tumor cells in vitro and causing hemorrhagic necrosis of transplantable tumors in mice. 1, 2 …
Clinical pharmacology of thalidomide
T Eriksson, S Björkman, P Höglund - European journal of clinical …, 2001 - Springer
Background: Thalidomide has a chiral centre, and the racemate of (R)-and (S)-thalidomide
was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to …
was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to …
Biologic therapy of inflammatory bowel disease
WJ Sandborn, SR Targan - Gastroenterology, 2002 - Elsevier
Advancing knowledge regarding the biology of chronic inflammation has led to the
development of specific biologic therapies that mechanistically target individual …
development of specific biologic therapies that mechanistically target individual …